Qpex Biopharma

Qpex Biopharma is a biotechnology company based in the United States, founded in 2018 and acquired by Shionogi, Inc in July 2023. The company's slogan "Focusing on Resistance in Antibiotic Development" reflects its mission to address drug resistance in infectious diseases. Qpex has a remarkable track record, having brought 4 antibiotic products to regulatory approvals over the past decade and has extensive experience in working with public-private partnerships, including Biomedical Advanced Research and Development Authority (BARDA), which led to the approval of the first antimicrobial drug product under that program in 2017. The company has received investments from New Enterprise Associates, Adams Street Partners, LYZZ Capital, Hatteras Venture Partners, and Stanford University Daper Fund, with the last investment being a $20.00M grant from Biomedical Advanced Research and Development Authority (BARDA) on 16 December 2019. Qpex is focused on creating innovative products and development strategies to overcome multi-drug resistance, aiming to deliver the right treatments to the right patients in the right settings. With its acquisition by Shionogi, Inc, Qpex is now part of the Shionogi Group Company, positioned for further growth and impact in the infectious disease sector.